What changed from existing technology?
This study tested a new treatment for severe knee osteoarthritis using special cells from fat tissue, showing it is safe and possible to use in humans.
This is the first study to evaluate the use of GMP-produced, cryopreserved autologous stromal vascular fraction in a clinical setting for knee osteoarthritis treatment.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
cal study evaluates the feasibility and safety of good manufacturing practice (GMP)–produced, cryopreserved autologous SVF administered in two separate injectio
Abstract ↗ologous SVF administered in two separate injections in patients with advanced knee OA, and reports exploratory, patient-reported clinical outcomes. Ten patien
Abstract ↗- 시제품·장치 구현 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This approach may be explored as a potential treatment option for patients with advanced knee osteoarthritis, pending further research.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.